The Janssen Pharmaceutical Companies of Johnson & Johnson Issues its 2019 Janssen U.S. Transparency Report
Johnson & Johnson Joins Other Companies in Signing a Landmark Communiqué on Expanded Global Access for COVID-19Did you enjoy reading this story? Click the heart.
Have Questions About Participating in a COVID-19 Vaccine Clinical Trial? A Doctor Overseeing a Study Helps Answer ThemDid you like reading this story? Click the heart to show your love.
Did you like taking this quiz? Click the heart to show your love.
Titusville, NJ – (April 8, 2020) – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson issued its 2019 Janssen U.S. Transparency Report, available at Janssen.com/USTransparencyReport.
Scott White, Company Group Chairman, North America Pharmaceuticals for Johnson & Johnson, issued the following statement on the release of the report:
Thanks to an open and competitive marketplace, the U.S. health system delivers innovative treatment choices and earlier access to groundbreaking medicines, yet out-of-pocket costs continue to be an issue for many people.
At Janssen, we’re helping lead the way to a stronger health system that works better for patients by supporting pro-competition policy solutions and affordable access to our innovations. As our 2019 Janssen U.S. Transparency Report shows, the average net price of our medicines continues to fall and we invested $39.4 billion in R&D over the last five years. That investment is bringing transformational medical advances for patients and is contributing to achievements like the major drop in cancer rates here in the U.S. over the last 25 years. Results like these highlight the urgency of reducing patients’ out-of-pocket costs and driving innovation that enables us to meet future unmet needs.